The size of the global intraosseous infusion devices market was valued at USD 5.37 billion in 2024 and is expected to grow at a CAGR of 7.2% and be worth USD 7.60 billion by 2029.
Intraosseous access is the first practical alternative for delayed peripheral or central intravenous access in emergencies, involving the vascular device with the end of the intraosseous catheter placed into the bone matrix, making it a route for primary means of vascular access in critically injured patients. Medications are introduced in the human bone marrow using intraosseous infusion to provide an entry point in systemic circulation. The devices used for these are called Intraosseous Infusion devices. It is used intravenous access is unavailable. It can be used both in adults and children. It is majorly used for drug administration and vascular entry.
Intraosseous infusion is advised for cardiopulmonary resuscitation when peripheral venous access fails, which is projected to boost the worldwide intraosseous infusion devices market over the forecast period. The global intraosseous infusion devices market is rapidly increasing, owing to an increase in emergency care cases and the prevalence of chronic conditions such as severe accidents, cardiovascular ailments, obesity, and serious burns, which increase the chances of hospitalization. Over the forecast period, the global intraosseous infusion devices market is predicted to develop due to an increase in emergency surgeries. The significant benefits it offers include a safe, efficient, stable, and multi-site placement for patients of all sizes and a device with Medication delivery equivalent to a central venous catheter. In addition, it has few contraindications, a meager complication rate, and a high success rate, driving the market's growth. Furthermore, the battery-powered devices are even handier, controlled, and make insertion easy since the medication delivery is directed into the vascular system with serum levels equivalent to intravenous administration.
Intraosseous Infusion instruments are becoming more common in military medical facilities and medical emergencies that arise from them. In the coming years, increased demand for critical and emergency procedures and a growing admission rate to critical and emergency facilities would likely benefit the global intraosseous infusion devices market. Due to its standard Luer-lock catheter, the use of intraosseous infusion is now increasingly used in adults too, which was restricted to pediatric resuscitation and military medicine only and is now preferred in advanced intensive care in adult to endotracheal route for the administration of drugs, like those of circulatory collapse due to diabetic ketoacidosis or severe dehydration, the market is expected to be driven. Patients aged six and under are considered healthy to take automated infusions. Intraosseous access can be performed by semi-skilled healthcare professionals with only minimal training. Furthermore, the launch of emergency medical training simulators is expected to help the global intraosseous infusion devices market expand.
Some of the other significant benefits owing to which the market for intraosseous infusion devices is growing at a rapid pace include its use in administering blood, delivering drugs at an adequate plasma concentration, its application in neonates, despite the ease of umbilical venous access, access to high flow rates using syringes for infusion of fluid, its access to children with burn injuries for rapid fluid administration, and its allowance for analysis of venous blood gases, the measurement of electrolytes, and hemoglobin concentration through the removal of bone marrow.
Other factors that impede the market expansion include an increased risk of compartment syndrome leading to the gushing of fluids and drugs into soft tissues, as well as restrictions on use in people with extreme osteoporosis and hypovolemic conditions. However, one review found that intraosseous access in out-of-hospital cardiac arrest is linked to the worsening recovery of spontaneous circulation and survival to hospital discharge. Also, pain can be significant during or after this technique since it may sometimes outweigh the injuries treated in some patients, according to a report, needed for appropriate local anesthesia-conscious patients. Extravasation, soft-tissue necrosis, bone fractures or damage to the growth plates, drug penetration, inflammation, subcutaneous abscess, osteomyelitis, and embolic complications are all risks associated with intraosseous access. The most popular complication is fluid extravasation.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Product Type, Technology, End-User, Route of Administration & Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
PerSys Medical, Aero Healthcare, Teleflex, Pyng Medical Corp |
The FAST1 device leads the market and will likely do so throughout the projected period. The FAST1 Intraosseous Infusion System establishes a sternal intraosseous access route for patients during the unavailability of standard venous access. It is designed to access a faster central circulation than tibial infusions with in-depth control to prevent severe injuries to the sternum. Pyng Medical's FAST1 Intraosseous infusion technology is widely used in military medical care facilities in personal combat and military crises. This method is primary and easy to use.
EZ-IO device is foreseen to dominate the market over the forecast period owing to its ability to aspirate bone marrow without palpable extravasation. In 2004, the EZ-IO device was approved by the Food and Drug Administration. Since then, had been used in prehospital settings using the same physiological concepts as the administration of liquids and medication into the blood. But at present, the aim is to present the experience of these inserts in the pediatric emergency department.
The impact-driven technology segment is expected to hold the largest market share during the forecast period. One of the two devices allows access to the sternum with a precise depth location using multiple needle probes. The central needle enters the sternal medullary cavity when pressure is applied, but the inability to reach the sternum during resuscitation is a potential drawback. The other version inserts the intraosseous needle into the tibia's medullary space using a spring-loaded injection mechanism. Both devices must be correctly stabilized to prevent harm to the patient or caregiver.
The battery-powered drill is also foreseen to hold a substantial market share across the forecast period owing to its efficient insertion and minimizing bone trauma during insertion. Furthermore, it is specifically designed to access the intraosseous space with a screwdriver and a set of needles at an appropriate depth, with the help of using different sizes of needles owing to the patient's age, weight, and tissue depth.
The humerus segment head is estimated to capture the largest market share. The IO infusion in the Head of the Humerus provides an excellent option for critically ill patients with impossible or difficult vascular access. It quickly establishes dependable vascular access thanks to the highest possible flow rates. In addition, it can provide a better route to resuscitation if you have a clear awareness of the indications and contraindications of this straightforward operation.
The IO infusion in the sternum is anticipated to grow due to its rapid delivery of vital fluids and medications, facilitating emergency resuscitation through the spinal cord space. Medical professionals consider the sternum as the recommended IO access since this route remains underused in civilian settings, mainly if the user requires higher flow rates, has trauma to the extremities, is new to IO devices, or administration of a fat-soluble drug has been planned.
The hospital segment holds the most significant growth. Hospitals are concentrating on increasing investment in R&D to enhance revenue share. Therefore, industry participants are anticipated throughout the forecast period to profit from the lucrative expansion of the intraosseous infusion investment market. Such advancements improve a company's existing portfolio, its regional and global presence, and its ability to endure growing competitive pressure. Therefore, during the projected period, the Cardiac Care segment will expand rapidly in terms of sales.
Geographically, the North American intraosseous infusion devices market is the leader among all the regions in the global market and is expected to remain leading in the forecast, as mentioned above period. The North American region currently leads the worldwide market and will likely continue to do so over the forecast period. The high prevalence of cardiovascular diseases, chronic illnesses, emergency medical situations, and obesity contribute significantly to the regional market's growth. Furthermore, numerous major market players in the area and their networks are projected to support market growth in North America.
The Europe intraosseous infusion devices market is the third-largest regional market. Furthermore, Europe is predicted to be the fastest expanding market in the global intraosseous infusion devices market in terms of revenue growth.
The intraosseous infusion devices market in Asia Pacific is the second-largest market and is expected to grow with the highest CAGR.
Latin America and MEA are also predicted to showcase robust growth in the forecast period.
Some prominent companies operating the global intraosseous infusion devices market profiled in the report are PerSys Medical, Aero Healthcare, Teleflex, Pyng Medical Corp, Biopsybell, Cook Medical Incorporated, and Aero Healthcare.
In November 2022, a diversified, commercial-stage medical technology company, PAVmed Inc., announced hosting a business update conference call and webcast to overview the company's operations and discuss growth strategies.
In August 2022, Becton Dickinson recalled Manual Intraosseous Screwdriver Kits, Needle Kits, and Motorized Intraosseous Screwdriver Kits used for accessing blood vessels through a patient's bone, which may delay treatment delivery.
This market research report on the global intraosseous infusion devices market has been segmented and sub-segmented into the following categories.
By Product Type
By Technology
By Route of Administration
By End User
By Region
Frequently Asked Questions
The global intraosseous infusion devices market size was valued at USD 5.01 billion in 2023.
Geographically, the North American intraosseous infusion devices market accounted for the largest share of the global market in 2023.
Yes, we have studied and included the COVID-19 impact on the global intraosseous infusion devices market in this report.
The global intraosseous infusion devices market is estimated to grow at a CAGR of 7.2% from 2024 to 2029.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region